SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri
SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen deprivation therapy — with enzalutamide — with a PSA decline of at least 30 per cent. Heather H Cheng MD PhD, who is a Senior Reseach Fellow at the Fred Hutchinson Cancer Research Center in Seattle, Washington, presented her results at a poster session of the 2014 ASCO Genitourinary Cancers Symposium.
CONTACT:
Heather H Cheng MD PhD
Senior Reseach Fellow
Fred Hutchinson Cancer Research Center
Seattle, Washington 98109
SOURCE:
2014 ASCO Genitourinary Symposium, San Francisco
Abstract 18
“The effect of prior abiraterone use on the activity of enzalutamide in men with mCRPC”
ABSTRACT LINK:
http://meetinglibrary.asco.org/content/124184-142
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon